News

Bonumose Announces Key Advisory and Leadership Appointments

Bonumose, Inc. – an enzyme technology company with solutions for sugar reduction and other globally critical industries – is pleased to announce the following appointments.

  • Dr. Andrew Fordyce has accepted a key advisory role with Bonumose. Dr. Fordyce most recently was Executive Vice President and Food & Beverage Divisional Head for Novozymes, a global leader in biological solutions. His experience includes executive management in both functional and business unit organizational structures and he has had a multifaceted career that has covered biotech innovation and business strategy, marketing and business portfolio management, and process engineering and application research. Over Dr. Fordyce’s 27-year career at Novozymes he served multiple management roles including 7 years on the Novozymes’ Executive Leadership Team. Dr. Fordyce is advising Bonumose on multiple aspects of the enzyme value chain, as well as general R&D and business matters.
  • Dr. Katie Whalen. Bonumose has appointed Dr. Whalen, Director of Innovation Delivery, to the additional role of Chief of Staff. Dr. Whalen has a PhD in Biochemistry and prior to Bonumose spent 5 years at Kalsec. In her expanded role, Dr. Whalen is Bonumose’s lead on identifying and filling gaps for organizational capacity development, and also is responsible for ensuring Bonumose maintains a positive culture while scaling its production, global sales, and new product development.
  • Robert Coward. Mr. Coward recently joined Bonumose as Vice President for Finance & Accounting. Mr. Coward was with Xerox (NASDAQ: XRX), an S&P 400 company, for 28 years. Throughout his career Mr. Coward has held increasingly senior leadership roles in finance as well as operations.
  • Ross Bartels. Mr. Bartels, a recent graduate of the University of Virginia School of Law, joined Bonumose as its first in-house legal counsel. Mr. Bartels areas of focus for Bonumose include intellectual property protection, regulatory and administrative law, and general legal matters. Bonumose has over 50 granted patents globally and many more patent applications pending, and also is engaging with food ingredient regulatory bodies globally.

Bonumose is based in Albemarle County, Virginia, and was selected as a Technology Pioneer by the World Economic Forum.

Recent News

10/21/2026

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free (DPF) facility, The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility, in Houston, Texas. United Therapeutics opened its first DPF facility in Christiansburg, Va. in 2024 to produce xenografts for ongoing clinical trials. …

10/20/2026

Supernus Reaches Key Milestone Toward Proposed Merger with Indivior Following Shareholder Approval

Supernus Pharmaceuticals, Inc. welcomed the decisive backing of shareholders today, who formally voted to approve the pending all-stock merger of equals. This vote marks an important milestone toward completing the merger announced in August 2026, with closing anticipated on November 2, 2026, subject to customary closing conditions. Following closing, the combined organization will officially commence …

10/20/2026

GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026

GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced 27 accepted scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are advancing scientific discovery, earlier diagnosis and more precise care. GeneDx research at ASHG 2026 highlights …